Core Insights - Phibro Animal Health Corporation (PAHC) is focusing on advancing its Animal Health business, which is expected to drive growth in the upcoming quarters [1] - The company has shown strong performance with a 39.9% increase in shares over the past year, significantly outperforming the industry and S&P 500 [2] - Recovery in Mineral Nutrition and Performance Products is contributing to overall growth, although macroeconomic conditions remain a concern [1][9] Animal Health Business - Phibro's key animal health products, including Medicated Feed Additives (MFAs) and nutritional specialty products, are enhancing animal nutrition and are crucial for growth [3] - The Animal Health business reported a 42% sales growth year over year, with MFAs and other product sales increasing by 68% [4][8] - Nutritional specialty products saw an 8% increase in net sales, driven by improved domestic dairy demand [4] Global Market Presence - Phibro's operations outside the United States contributed approximately 40% to total revenues during the fiscal third quarter [6] - The company is targeting high-growth regions such as Brazil, China, India, and Southeast Asia, where livestock production growth rates are expected to exceed average levels [5] Mineral Nutrition and Performance Products - The Mineral Nutrition business grew 4% year over year, supported by increased sales volume and pricing [7] - Performance Products experienced a 28% year-over-year sales increase due to rising demand for personal care product ingredients [7][8] Macroeconomic Challenges - Phibro's operations are impacted by economic sanctions, supply chain disruptions, and inflationary pressures, particularly due to the ongoing conflict between Russia and Ukraine [9] - The cost of goods sold increased by 32.5% from the prior year, reflecting the adverse macroeconomic environment [9] Financial Estimates - The Zacks Consensus Estimate for fiscal 2025 earnings per share (EPS) has increased by 1.5% to $2.04, with revenue estimates at $1.28 billion, indicating a 25.6% rise from the previous year [10]

中国经济网北京6月5日讯5月30日，南方都市报发布《3年跑输基准超10%将降薪哪些基金经理"亮红灯"？》一文。文 中称，截至5月21日，全市场成立满三年、现任基金经理管理时长超过三年的公募基金共有近6000只(注：同一产品不 同份额，只统计一次)，其中，1341只基金近三年累计收益率低于同期业绩比较基准超10个百分点，涉及735位基金经 理。 在跑输基准的基金中，有31只基金产品近三年累计收益率低于基准超50个百分点，这其中包括金鹰基金韩广哲管理的 金鹰改革红利等多只产品。 金鹰改革红利混合成立于2015年12月2日，截至2025年6月4日，该基金近1年、近2年、近3年的阶段涨幅分别 为-13.41%、-37.29%、-49.62%，同期同类平均涨幅为7.40%、-2.84%、-5.73%，同期沪深300涨幅为7.00%、 0.18%、-5.40%。截至2025年6月4日，该基金累计净值1.3170元。 据一季报披露，金鹰改革红利混合保持了中高水平股票仓位，配置以成长风格、顺周期为主，重点布局了消费电子供 应链龙头公司、半导体芯片制造、整车智驾应用、工程机械、AI+医疗、创新药等板块，减持了半导体设备、银行等 ...

2025 Baird Global Consumer, Technology & Services Conference Bill Presley, President and CEO Jon Douyard, Executive Vice President of Finance, Chief Financial Officer and Treasurer Gentherm, Inc. | June 4, 2025 Proprietary © Gentherm Forward-Looking Statements Except for historical information contained herein, statements in this presentation are forward-looking statements that are made by Gentherm Incorporated (the "Company") pursuant to the safe harbor provisions of the Private Securities Litigation Refor ...

Company Overview - Hims & Hers Health, Inc. is a consumer-centric health and wellness platform based in San Francisco, CA, redefining healthcare through personalized solutions and seamless digital access [11] - The company specializes in subscription-based services and retail partnerships, addressing a broad range of health needs across key therapeutic categories [11] - HIMS operates under dual revenue streams: online subscriptions and wholesale retail [11] Investment Rating - HIMS is currently rated 2 (Buy) on the Zacks Rank, indicating a favorable investment outlook [12] - The company has a VGM Score of A, suggesting strong overall performance across value, growth, and momentum metrics [12] Momentum and Earnings Estimates - HIMS has a Momentum Style Score of B, with shares increasing by 35.6% over the past four weeks, indicating strong upward price momentum [12] - Six analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.10 to $0.73 per share [12] - The company boasts an average earnings surprise of 19.6%, reflecting its ability to exceed earnings expectations [12] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, HIMS is positioned as a strong candidate for investors' short lists [13]

Core Insights - STERIS is enhancing its product offerings through new acquisitions and partnerships, currently holding a Zacks Rank 2 (Buy) [1] Group 1: Growth Drivers - The Healthcare segment of STERIS is benefiting from the successful market adoption of its infection prevention consumables and capital equipment, with a reported revenue growth of 5% year over year for Q4 fiscal 2025 [2] - The Applied Sterilization Technologies (AST) division saw a 9% reported growth year over year in Q4 fiscal 2025, driven by a 6% increase in service revenues, with organic revenues in high single digits [3] - STERIS is experiencing increased bioprocessing demand, while global demand from MedTech customers remains stable [3] Group 2: Strategic Acquisitions - STERIS frequently engages in strategic acquisitions and joint ventures, including the recent purchase of surgical instrumentation and sterilization container assets from BD, which enhances its Healthcare product offerings [4] - The company anticipates a strong fiscal year ahead, with reported revenues from continuing operations expected to grow approximately 6-7% in fiscal 2026 [4] Group 3: Stock Performance - Over the past three months, STERIS shares have risen 13.6%, contrasting with an 11.8% dip in the industry, driven by sustained growth in bioprocessing demand and strategic acquisitions [5]

Core Insights - Doximity reported strong fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 38 cents, exceeding the Zacks Consensus Estimate of 27 cents by 40.7% and up from 25 cents in the prior-year quarter [1] - Total revenues for fiscal 2025 increased by 20% year over year to $570.4 million, with subscription revenues rising 21% to $543.8 million [3] - The company’s fiscal 2026 revenue guidance is projected between $619 million and $631 million, slightly below the Zacks Consensus Estimate of $627 million [8] Revenue Performance - Doximity's total revenues for the fourth quarter grew 17% year over year to $138.3 million, surpassing the Zacks Consensus Estimate by 3.4% [2] - Subscription revenues accounted for $131.9 million, also reflecting a 17% year-over-year increase [2] - The company achieved record highs in unique active users across various metrics, with over 620,000 unique active prescribers utilizing its workflow tools [2][9] Margin and Profitability - Adjusted gross profit for the fourth quarter was $126.5 million, up 17.3% from the previous year, with an adjusted gross margin of 91.4% [4] - Total adjusted operating income reached $68 million, marking a 23.7% increase year over year, and the adjusted operating margin improved to 49.1% [5] Financial Position - Doximity ended the fiscal fourth quarter with cash, cash equivalents, and marketable securities totaling $915.7 million, an increase from $844.9 million in the previous quarter [7] - Total assets rose to $1.26 billion, up from $1.17 billion sequentially [7] Strategic Initiatives - The company is heavily investing in AI to enhance clinician tools and pharmaceutical client solutions, aiming to improve ROI and predictability [10] - Doximity's AI features, including document analysis and clinical summarization, have gained traction among physicians, contributing to increased platform engagement [9][10]

Core Viewpoint - Solventum (SOLV) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $1.34, exceeding estimates, although showing a year-over-year decline of 35.6% [1]. Financial Performance - Adjusted EPS of $1.34 beat the Zacks Consensus Estimate of $1.19 by 12.6%, while GAAP EPS was 78 cents, down 43.1% year over year [1]. - Revenues reached $2.07 billion, reflecting a 2.6% increase from the prior year, with organic sales growth of 4.3%, surpassing estimates by 3.4% [1]. - Adjusted gross profit was $1.15 billion, down 1.9% year over year, with an adjusted gross margin of 55.6%, a decrease of approximately 260 basis points [8]. - Adjusted operating income totaled $407 million, down 15.9% year over year, with an adjusted operating margin of 19.7%, down approximately 430 basis points [9]. Segment Performance - MedSurg segment revenues were $1.16 billion, up 3.4% reportedly and 8.2% organically year over year, driven by strong volumes in IV site management and hospital consumables [3]. - Dental Solutions revenues totaled $328 million, down 2.1% year over year but up 0.4% organically, with strong sales in Restorative offsetting weak performance in Core Orthodontics [4]. - HIS segment revenues amounted to $329 million, up 3.6% reportedly and 3.9% organically, driven by the adoption of 360 Encompass revenue cycle management [5]. - Purification and Filtration segment revenues were $242 million, down 0.9% year over year but up 2.2% organically, supported by strength in bioprocessing filtration [7]. Financial Position - Solventum ended the first quarter with cash, cash equivalents, and investments of $534 million, down from $762 million in the previous quarter [10]. - Total assets increased to $14.52 billion from $14.46 billion in the previous quarter [10]. Guidance - The company raised its sales guidance for 2025, now expecting organic sales growth of 1.5-2.5%, up from the previous 1-2% [11]. - Adjusted EPS guidance remains in the range of $5.45-$5.65, with the Zacks Consensus Estimate at $5.48 per share [11]. Strategic Outlook - Solventum is undergoing a three-phase restructuring program post-separation from 3M, focusing on debt reduction, portfolio optimization, and operational efficiency, expected to enhance long-term prospects [13].

Core Viewpoint - Acadia Healthcare Company, Inc. (ACHC) is expected to report first-quarter 2025 results on May 12, with earnings estimated at 42 cents per share and revenues at $770.5 million, indicating a year-over-year earnings decline of 50% but a slight revenue growth of 0.3% [1][2]. Financial Estimates - First-quarter earnings estimates have declined by 8 cents per share over the past 60 days, reflecting a significant year-over-year decrease [2]. - For the full year 2025, the revenue estimate for Acadia Healthcare is $3.33 billion, representing a year-over-year increase of 5.7%, while the EPS estimate is $2.76, indicating a decline of 16.4% year-over-year [2]. Recent Performance - Acadia Healthcare has beaten earnings estimates in three of the last four quarters, with an average surprise of negative 0.4% [3]. Earnings Prediction Model - The current model does not predict an earnings beat for Acadia Healthcare, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [4]. Revenue Drivers - Revenue per patient day is estimated to rise by 2% year-over-year, and revenues from Residential Treatment Centers are expected to increase by 9.7% from $85.6 million a year ago [6]. - U.S. same-facility admissions are projected to show a marginal increase, while revenues from Specialty Treatment Facilities are expected to rise by 0.1% from $143.8 million [7]. Expense Concerns - Rising expenses are anticipated to impact profit levels, with total expenses expected to increase by more than 11% due to higher salaries, wages, benefits, and other operating costs [8]. - Supply costs are also expected to rise due to increased utilization [8]. Revenue Declines in Specific Areas - Revenues from Acute Inpatient Psychiatric Facilities are projected to decrease by 1.3% from $401.1 million, and same-facility patient days are expected to decline by 1.1% year-over-year [9]. - Comprehensive Treatment Centers' revenues are estimated to fall by 0.5% from $132.2 million [9].

Financial Data and Key Metrics Changes - The company reported flat sequential sales and flat year-over-year sales on a pro forma basis, attributed to a successful new business program despite a softening base business [6][7] - Adjusted gross margins were 16.9%, with a target to reach 19% to 20% over five years [14] - Adjusted EBITDA for the quarter was $10,600,000, with a full-year guidance range of $53,000,000 to $63,000,000 [15][48] - Working capital was $84,800,000, down $4,600,000 year-over-year, representing 19.1% of trailing twelve-month sales [16][36] Business Line Data and Key Metrics Changes - In the Power Solutions segment, net sales were $43,500,000, down from $48,200,000, primarily due to the impact of the Lubbock facility and unfavorable foreign exchange [42] - The Mobile Solutions segment reported net sales of $62,200,000, down from $73,100,000, impacted by rationalized business and lower automotive volumes [45] Market Data and Key Metrics Changes - The automotive market is experiencing a shift towards hybrid vehicles, which is beneficial for the company as it allows for the use of existing assets [57][58] - The company is seeing increased activity in tariff-related RFQs, particularly in reshoring opportunities from Canada and China [53][56] Company Strategy and Development Direction - The company is focusing on a profitable immediate growth strategy (PIGS) to ramp up new business, with 120 programs worth $55,000,000 in annualized sales expected to ramp up this year [8][10] - A significant transformation plan is underway, with 70% completion, focusing on enhancing leadership and addressing underperforming areas [17][18] Management's Comments on Operating Environment and Future Outlook - Management noted that business uncertainty has increased, leading to lighter sales than planned, particularly in global automotive [6][9] - The company is optimistic about both 2025 and long-term goals, with a focus on cost reduction and operational efficiency [12][49] Other Important Information - The company is initiating free cash flow guidance in the range of $14,000,000 to $16,000,000 for the year, reflecting improved margin capture and anticipated proceeds from the CARES Act [48] Q&A Session Summary Question: Can you provide more detail on tariff-related RFQs? - Management indicated that there is significant activity in reshoring opportunities from Canada and China, with a mix of new capital and reuse of existing capital [53][56] Question: How is the automotive market affecting new business opportunities? - The shift towards hybrid vehicles is seen as beneficial, allowing the company to utilize existing assets while also entering new markets for EV components [57][58] Question: Can you elaborate on the $55,000,000 in new business wins? - The timing for these wins is expected to be weighted towards the second half of the year, with a ramp-up period of three to six months for immediate programs [65][66] Question: What about the $15,000,000 cost savings target? - The cost savings are expected to be evenly distributed throughout the year, with some back-end loading [70] Question: Are there any more plant closures expected? - There are two additional plants under evaluation for potential closure, but no firm plans have been established yet [72]

Financial Data and Key Metrics Changes - The company reported net sales of $105.7 million for Q1 2025, a decline of $15.5 million compared to the previous year [42] - Adjusted gross margins were 16.9%, with adjusted EBITDA at $10.6 million, down from $11.3 million year-over-year [15][42] - Adjusted operating income was $2 million, an increase of $2.7 million quarter-on-quarter [15][43] Business Line Data and Key Metrics Changes - In the Power Solutions segment, net sales were $43.5 million, down $4.7 million from the prior year, primarily due to the impact of the Lubbock facility [43] - The Mobile Solutions segment reported net sales of $62.2 million, a decrease of $10.9 million year-over-year, driven by lower automotive volumes and unfavorable foreign exchange impacts [46] Market Data and Key Metrics Changes - The company noted that global automotive sales, which account for about 40% of total sales, experienced a downturn, leading to flat sequential and year-over-year sales [7][8] - The company is seeing a shift in the automotive market towards hybrids, which is beneficial for leveraging existing assets [58] Company Strategy and Development Direction - The company is focusing on a "Profitable Immediate Growth Strategy" (PIGS) to ramp up new business, with 120 programs expected to generate $55 million in annualized sales [9][10] - A significant transformation plan is underway, with 70% completion, aimed at enhancing leadership and addressing underperforming areas [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's outlook for 2025, despite current market uncertainties, and reiterated guidance for EBITDA and new business awards [10][49] - The company is initiating free cash flow guidance of $14 million to $16 million for the year, reflecting improved margin capture and cost reduction efforts [49] Other Important Information - The company has a working capital of $84.8 million, down from the previous year, and aims to further reduce it by $5 million over the next two quarters [16][37] - The company is actively pursuing new business opportunities in the medical sector, with a $40 million pipeline [30] Q&A Session Summary Question: Can you provide more detail on tariff-related RFQs? - Management noted increased activity in reshoring opportunities from Canada and China, primarily in the automotive sector, with a mix of new and existing capital required [54][55] Question: How is the automotive market affecting new business opportunities? - The shift towards hybrids is seen as beneficial, allowing the company to utilize legacy assets effectively while also entering new markets for EV components [58][59] Question: Can you elaborate on the $55 million in new business wins? - The new business is expected to ramp up over the next three to six months, with a significant portion impacting the second half of the year [66][67] Question: What is the status of the $15 million cost savings target? - The cost savings are expected to be evenly distributed throughout the year, with some back-end loading [71] Question: Are there plans for further plant closures? - There are two additional plants under evaluation for potential closure, but no firm plans have been established yet [73] Question: Does the free cash flow guidance include the CARES Act refund? - Yes, the guidance includes approximately $12.3 million from the CARES Act [78]